Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $48.45 | Total: $242.25 |
| 1 | 10 | $41.04 | Total: $410.40 |
| 1 | 25 | $34.77 | Total: $869.25 |
| 1 | 50 | $29.64 | Total: $1,482.00 |
| 1 | 100 | $25.65 | Total: $2,565.00 |
Overview
BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity.
Chemical Properties
| Molecular Formula | C23H25F3N4O3 |
| Molecular Weight | 462.46 |
| CAS Numbers | 2230836-55-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1cc2nc(C)nc(N[C@H](C)c3cc(N)cc(c3)C(F)(F)F)c2cc1O[C@H]1CCOC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Marco H Hofmann, et al. Abstract PL06-01 Discovery of BI-3406 A potent and selective SOS1 KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.